Scarica l'app Stockscreener
2.82
1.74%
-0.05
Dopo l'orario di chiusura:
2.83
0.01
+0.35%
Black Diamond Therapeutics Inc Borsa (BDTX) Ultime notizie
Implied volatility surging for Black Diamond Therapeutics stock options - MSN
HC Wainwright Issues Positive Forecast for BDTX Earnings - MarketBeat
Why is Black Diamond (BDTX) up 19.3% since last earnings report? - MSN
[ARS] Black Diamond Therapeutics, Inc. SEC Filing - Stock Titan
Black Diamond Therapeutics (BDTX) outlines 2026 virtual meeting and Say-on-Pay votes - Stock Titan
BDTX Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Given New $11.00 Price Target at BTIG Research - MarketBeat
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Implied Volatility Surging for Black Diamond Therapeutics Stock Options - Zacks Investment Research
BDTX: What silevertinib data say about EGFR NSCLC upside - MSN
Will Upcoming Catalysts Help Black Diamond Investors Breathe Easy? - RTTNews
Black Diamond stock: Weighing catalysts vs. concentration - MSN
Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy - MarketBeat
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize - TradingView
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right - Yahoo Finance
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks - TradingView
BlackDiamond (BDTX) Stock: Technical Momentum Review | Q4 2025: Earnings Fall ShortBuyback Report - Xã Châu Thành
BDTX (Black Diamond Therapeutics Inc.) shares rise nearly 8 percent even as fourth quarter 2025 earnings fall well below analyst estimates.Community Sell Signals - UBND thành phố Hải Phòng
Black Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual Meeting - Quiver Quantitative
Black Diamond Therapeutics Announces Oral Presentation of - GlobeNewswire
BlackDiamond (BDTX) Stock Options Volume (Grinds Higher) 2026-04-20High Yield Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
BlackDiamond (BDTX) Stock: Why Day Traders Love It (+4.79%) 2026-04-18Social Momentum Signals - UBND thành phố Hải Phòng
Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program - MSN
Black Diamond Sued Over Patented Cancer Drug Discovery Methods - Bloomberg Law News
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? - Yahoo Finance
BlackDiamond (BDTX) Stock Adds to Position (Buying Pressure) 2026-04-15Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
Trading Action: Will Black Diamond Therapeutics Inc benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - baoquankhu1.vn
Volatility Watch: Will Black Diamond Therapeutics Inc benefit from AI trends2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Black Diamond Therapeutics Receives 'Moderate Buy' Rating from Analysts - National Today
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Market Fear: Does Black Diamond Therapeutics Inc outperform in volatile marketsGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Invesco Senior Loan Fund's Black Diamond Therapeutics Inc(BDTX) Holding History - GuruFocus
Investment Recap: How does Black Diamond Therapeutics Inc score in quality rankingsWeekly Investment Summary & Long-Term Safe Return Strategies - baoquankhu1.vn
Risk Recap: Is Black Diamond Therapeutics Inc part of any ETFDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
BDTX: Insights from Silevertinib Data on EGFR NSCLC Growth Potential - Bitget
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026 - TradingView
Black Diamond Stock: Weighing Catalysts vs. Concentration - Yahoo Finance
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside - TradingView
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):